Two new studies to be presented at the SLEEP 2024 annual meeting show that narcolepsy is an independent risk factor for cardiovascular disease and adverse cardiac events.
First Oral JAK Inhibitor Approved for Severe Alopecia Areata in Teens
The FDA approved the Janus kinase (JAK) inhibitor ritlecitinib (Litfulo) for adults and adolescents with severe alopecia areata. Ritlecitinib is the second oral JAK inhibitor
June 27, 2023